Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer

Neoplasma

Volumn 54, Issue 5, 2007, Pages 365-373

  Papadopoulou, E ^a   Simopoulos, K ^a   Tripsianis, G ^a   Tentes, I ^a   Anagnostopoulos, K ^a   Sivridis, E ^a   Galazios, G ^a   Kortsaris, A ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Breast cancer; c erbB 2; HER 2; Polymorphism; Relative risk

Indexed keywords

ISOLEUCINE; VALINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ALLELIC IMBALANCE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER STAGING; CODON; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENOTYPE; GREECE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; ONCOGENE NEU; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; GENETICS; MENOPAUSE; MIDDLE AGED; PATHOLOGY; RELIGION;

ADULT; AGED; ALLELIC IMBALANCE; BREAST NEOPLASMS; CHRISTIANITY; CODON; ETHNIC GROUPS; FEMALE; GREECE; HUMANS; ISLAM; MENOPAUSE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2;

EID: 35449007285     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. BARGMANN CI, HUNG MC, WEINBERG RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986; 45:649-657
2. AKIYAMA T, SUDO C, OGUWARA H et al. The product of the c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-1646 (Pubitemid 16095607)
3. PELES E, LEVY RB, OR E, ULLRICH A, YARDEN Y. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. EMBO J 1991; 10: 2077-2086
4. DOUGALL WC, QIAN X, PETERSON NC et al. The neuoncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 1994;9:2109-2123 (Pubitemid 24228659)
5. HELDIN CH. Dimerization of cell surface receptors in signal transduction. Cell 1995; 80:213-223
6. SLAMON DJ, CLARK GM, WONG SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182
7. SLAMON DJ, GODOLPHIN W, JONES LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712. (Pubitemid 19147683)
8. KAMEDA T, YASUI W, YOSHIDA K et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res 1990; 50:8002-8009
9. VOLLMER RT, HUMPHREY PA, SWANSON PE, WICK MR, Hudson ML. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erbB-2, epidermal growth factor receptor, and bcl-2. Cancer 1998; 82: 715-723
10. MOROTE J, DE TORRES I, CACERES C et al. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer. Int J Cancer 1999; 84:421-425. (Pubitemid 29337131)
11. REVILLION F, BONNETERRE J and PEYRAT JP. ERB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34:791-808. (Pubitemid 28248487)
12. MENARD S, PUPA SM, CAMPIGLIO M, TAGLIABUE E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-6578.
13. ROSS JS, FLETCHER JA, LINETTE GP et al. The Her-2/ neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307-325.
14. SLAMON DJ, LEYLAND-JONES B, SHAK S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 44:783-792
15. BASELGA J, NORTON L, ALBANELL J, KIM YM, MENDELSOHN J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998: 58:2825-2831
16. NABHOLTZ JM, REESE DM, LINDSAY MA, RIVA A. HER2-positive breast cancer: update on Breast Cancer International Research Group Trials. Clin Breast Cancer 2002; 2(Suppl): S75-9.
17. PAPEWALLIS J, NIKITIN A and RAJEWSKY M. G to A polymorphism at amino acid codon 655 of the human erbB- 2/HER-2 gene. Nucleic Acids Res 1991;19:5452.
18. XIE D, SHU X, DENG Z et al. Population-based, case-control study of HER-2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000; 92: 412-417. (Pubitemid 30154823)
19. ZUBOR P, VOJVODOVA A et al. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia. Neoplasma 2006; 3(5): 49-55. (Pubitemid 43206939)
20. PINTO D, VASCONCELOS A, COSTA A et al. HER2 polymorphism and breast cancer risk in Portugal. European J. Cancer Prevention 2004; 13:177-181. (Pubitemid 38780673)
21. RUTTER J.L, CHATTERJEE N, WACHOLDER S and STRUEWING J. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. Epidemiology 2003 14: 694-700. (Pubitemid 40417017)
22. MONTGOMERY K, GERTING D, BAXTER S et al. The HER2 I655V polymorphism and risk of breast cancer in women < Age 40 Years. Cancer Epidemiology, Biomarkers and Prevention 2003; 12: 1109-1111.
23. MILLIKAN R, EATON A, WORLEY K et al. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Research and Treatment 2003; 79: 355-364.
24. AN HJ, KIM NK et al. Her2 genotype and breast cancer progression in Korean women. Pathol Int 2005; 55: 48-52.
25. FRANK B, HEMMINKI K et al. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis 2005; 26: 643-647. (Pubitemid 41214155)
26. BENUSIGLIO P, LESUEUR F, LUCCARINI C et al. Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 2005; 7: 204-209.
27. BAXTER S AND CAMPBELL I. Re: Population-based, case-control study of HER-2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2001; 93: 557.
28. AKISIK E AND DALAY N. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 2004; 76(3): 260-263.
29. KALEMI T, LAMBROPOULOS A, GUEORGUIEV M et al. The association of p53 mutations and p53 codon 72, Her2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece Cancer Letters 2005; 222:57-65.
30. KESHAVA C, MCCANLIES E. et al Distribution of HER2V655 genotypes in breast cancer cases and controls in the United States. Cancer Letters 2001; 173: 37-41.
31. KAMALI-SARVESTANI E, TALEI A. and MERAT A. Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Letters 2004; 215: 83-87.
32. KURAOKA K, MATSUMURA S, HAMA Y et al. A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer. Int J Cancer 2003; 107:593-596
33. WANG L, HABUCHI T, TAKAHASHI T et al. No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer. Int J Cancer 2002; 97:787-790. (Pubitemid 34106333)
34. PINTO D, PEREIRA D, PORTELA C et al. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochemical and Biophysical Research Communications 2005; 335:1173-1178. (Pubitemid 41215541)
35. UEDA M, HUNG YC, TERAI Y et al. HER-2 codon 655 polymorphism in cervical carcinogenesis. Int J Gynecol Cancer 2006; 16: 325-328.
36. SEKINE Y, HASUMI M, OHTAKE N et al. HER-2 gene polymorphism at codon 655 in familial prostate cancer in a Japanese population. Asia-Pacific Journal of Clinical Oncology 2005; 1:133-137.
37. YOKOMIZO A, KOGA H, KINUKAWA N et al. Association of HER-2 polymorphism with Japanese sporadic prostate cancer susceptibility. Prostate 2005; 62:49-53. (Pubitemid 39614293)
38. AMEYAW M, TAYEB M, THORNTON N et al. Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet 2002; 47: 172-175.
39. BLOOM HJG, RICHARDSON WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-377.
40. Union Intrernational Contre Cancer. UICC TNM classification of malignant tumors, 4th Ed. Berlin: Springer-Verlag, 1992.
41. YARDEN Y and SLIWKOWSKI MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
42. ROSS JS AND FLETCHER JA. HER-2/neu (c-erb-B2) Gene and Protein in Breast Cancer. Am J Clin Pathol 1999; 112(Suppl. 1): 53-67.
43. ZHENG W, KATAOKA N, XIE D, YOUNG SR. Re: Population- based, case-control study of HER-2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2001; 93:558-559
44. WANG-GOHRKE S, CHANG-CLAUDE J. Re: Population- based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2001; 93: 1657-1659 (Pubitemid 33094876)
45. NELSON SE, GOULD MN, HAMPTON JM and TRENTHAM-DIETZ A. A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res 2005; 7: R357-R364.
46. COX DG, HANKINSON SE and HUNTER DJ. The erbB2/ HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet. Genomics 2005; 15: 447-450. (Pubitemid 41017592)
47. BONNIER P, ROMAIN S, CHARPIN C et al. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer 1995; 62:138-144.
48. NIXON AJ, NEUBERG D, HAYES DF et al. Relationship of patient age to pathologic features of the tumour and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994; 12: 888-894. (Pubitemid 24145313)
49. FLEISHMAN SJ, SCHLESSINGER J and BEN-TAL N. A putative molecular-activation switch in the transmembrane domain of erbB-2. Proc Natl Acad Sci 2002; 99(25):15937-15940
50. MILES DW. Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting. Breast cancer Res 2001; 3: 380-384. (Pubitemid 34196364)
51. TAKANO K, OGASAHARA K et al. Contribution of hydrophobic residues to the stability of human lysozyme: calorimetric studies and X-ray structural analysis of the five isoleucine to valine mutants. J Mol Biol 1995; 254: 62-76.